Akzo Pharma's Fall and Rise

The recent meltdown at Akzo Nobel's Pharma unit was caused by a perfect storm of genericization, macroeconomic gloom, pipeline delays and product underperformance. But Akzo Pharma hopes that by beefing up R&D and cutting costs through restructuring, it can return to growth in 2005.

After many consecutive years of double digit annual growth in its pharmaceuticals business, Akzo Nobel NV has warned that the next few years will be something entirely different for investors in the Dutch pharmaceuticals, chemicals and paints conglomerate. Most observers—and indeed Akzo Nobel itself—expected a slow-down in the pharma business; but the extent of the fall has nevertheless been spectacular. Management expects pharma sales to fall by at least 10% in 2003.

A conglomerate structure, so the argument goes, provides a buffer against the mood swings of the global economy; pharmaceuticals divisions...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo